The long-term goal of this project is to elucidate the deregulated survival signaling pathways critical for prostate cancer development and progression. Several recent studies demonstrated that a reciprocal regulation of the two major survival signaling pathways driven by PI3K-AKT and the androgen receptor (AR) in prostate cancer cells plays an important role in castration resistance. Simultaneous inhibition of both pathways has a more superior efficacy in attenuating tumor growth in preclinical models. Therefore, fully understanding the mechanisms by which these two survival pathways are regulated in prostate cancer will provide molecular basis for development of new effective therapy. We have recently identified the ubiquitin E3 ligase RNF6, which is overexpressed in castration- resistant prostate cancer, as a co-factor of AR. Inhibition of RNF6 expression compromises AR transcriptional activity and attenuates tumor growth under androgen-depleted conditions, indicating an important role of RNF6 in prostate progression. To further understand the role of RNF6 in prostate, we have generated a mouse model with targeted disruption in the Rnf6 locus. Rnf6-deficient mice are defective in prostate development, which is accompanied with compromised multiple signaling pathways, including AR and Akt pathways. We showed that the expression of several AR-targeting microRNAs is up-regulated in Rnf6-deficient prostates, concomitant with a reduction of AR protein level. In addition, we have identified RNF6 as a potential new regulator of AKT activation. We hypothesize that RNF6 may function as a key regulator of multiple survival signaling pathways critical for prostate cancer progression via modulating the activity of both AR and AKT, and inactivation of RNF6 may effectively attenuate the growth of castration-resistant prostate tumors by inhibiting both AR and AKT- mediated survival signaling.
Three specific aims are proposed:
Aim 1) Delineate the mechanisms by which RNF6 modulates AR expression in prostate cancer cells;
Aim 2) Investigate the mechanisms by which RNF6 modulates AKT activity;
Aim 3) Examine the effects of inactivation of Rnf6 and its downstream effectors on castration-resistant prostate cancer in preclinical models.

Public Health Relevance

Prostate cancer (PCa) is the most commonly diagnosed cancer among men. Androgen ablation therapy is one of the commonly used treatments for advanced prostate cancer patients. However, most patients eventually develop castration-resistant tumors, which are highly aggressive and resistant to conventional therapies. To improve PCa therapy, it will be necessary to address the problems of progression to androgen independence. Therefore, understanding the biological mechanisms involved in androgen-independent growth has emerged as a fundamental and urgent issue in PCa research. We have shown that RNF6 is overexpressed in castration-resistant PCa and regulates survival signaling pathways critical for PCa cell growth. In this application, we have established a mouse model with deletion of Rnf6 to study its role in prostate and to test whether inhibition of Rnf6 expression is a possible approach to block PCa development and progression in animal model. This study will provide molecular basis for development of new effective therapy for PCa.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA169524-02
Application #
8623110
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2013-03-01
Project End
2018-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
2
Fiscal Year
2014
Total Cost
$286,662
Indirect Cost
$99,912
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201